Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031755 | 1.00 | SLC7A5 (0.44) | SLC7A5SLC1A1SLC1A3SLC1A2TSHR | |
| SCHEMBL17667384 | 1.00 | SLC7A5 (0.44) | SLC7A5SLC1A1SLC1A3SLC1A2TSHR | |
| SCHEMBL1927791 | 0.82 | SLC7A5 (0.43) | SLC7A5SLC1A1SLC1A3SLC1A2TSHR | |
| SCHEMBL29205847 | 0.80 | TSHR (0.42) | SLC7A5SLC1A1TSHRHSD17B10MGAM | |
| SCHEMBL5077875 | 0.79 | TSHR (0.50) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL5081302 | 0.79 | TSHR (0.50) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL23277581 | 0.79 | SLC7A5 (0.40) | SLC7A5SLC1A1SLC1A3SLC1A2MMP1 | |
| SCHEMBL4706239 | 0.79 | CYP2D6 (0.41) | SLC7A5SLC1A1SLC1A3SLC1A2GAA | |
| SCHEMBL333966 | 0.79 | CYP2D6 (0.41) | SLC7A5SLC1A1SLC1A3SLC1A2GAA | |
| SCHEMBL27419703 | 0.79 | CYP2D6 (0.41) | SLC7A5SLC1A1SLC1A3SLC1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072615-B | Preparation method of vipatavir intermediate | 上海法默生物科技有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-113072615-A | Preparation method of vipatavir intermediate | 上海法默生物科技有限公司 | 2021-07-06 | — | — | CN | claimed |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | claimed |
| US-10118912-B2 | Process for the preparation of Ledipasvir | OPTIMUS DRUGS PRIVATE LTD. (IN) | 2018-11-06 | — | — | US | claimed |
| EP-3237405-A1 | POLYMORPHIC FORMS OF METHYL((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL) CARBONYL)-2-METHYLPROPYL)CARBAMATE AND SALTS THEREOF | Cipla Limited (IN) | 2017-11-01 | — | — | EP | claimed |
| US-20170197944-A1 | PROCESS FOR THE PREPARATION OF LEDIPASVIR | Optimus Drugs, LLC (IN) | 2017-07-13 | — | — | US | claimed |
| WO-2017072596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEDIPASVIR | OPTIMUS DRUGS (P) LTD (IN) | 2017-05-04 | — | — | WO | claimed |
| WO-2016102979-A1 | POLYMORPHIC FORMS OF METHYL((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL) CARBONYL)-2-METHYLPROPYL)CARBAMATE AND SALTS THEREOF | CIPLA LIMITED (IN) | 2016-06-30 | — | — | WO | claimed |
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-14 | — | — | US | disclosed |
| CN-119901859-A | Analysis method for purity of fluorenylmethoxycarbonyl-L-valine and related substances | 苏州默迪夫生物科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250122219-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025080863-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-3686185-B1 | FLUORENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING HCV-RELATED DISEASE | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2023-12-13 | — | — | EP | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2373172-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-1513819-A1 | PROCESS FOR PREPARING (S)-TETRAHYDRO-A-(1-METHYLETHYL)-2-OXO-1(2H)- PYRIMIDINEACETIC ACID | Clariant Life Science Molecules (Italia) S.p.A. (IT) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101971-A1 | PROCESS FOR PREPARING (S)-TETRAHYDRO-A-(1-METHYLETHYL)-2-OXO-1(2H)- PYRIMIDINEACETIC ACID | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SLC7A5 2289/4885SLC1A1 4287/4885SLC1A3 4380/4885 |
| US-20250122219-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | SLC7A5 1256/4885SLC1A1 1813/4885SLC1A3 2560/4885 |
| US-10118912-B2 | Process for the preparation of Ledipasvir | SAMHD1, POLI, PNP | SLC7A5 2620/4885SLC1A1 4259/4885SLC1A3 4013/4885 |
| US-20170197944-A1 | PROCESS FOR THE PREPARATION OF LEDIPASVIR | SAMHD1, POLI, PNP | SLC7A5 2620/4885SLC1A1 4259/4885SLC1A3 4013/4885 |
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | SLC7A5 3981/4885SLC1A1 4527/4885SLC1A3 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.